Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
ROCK CREEK PHARMACEUTICALS, INC. (RCPI)
|
Add to portfolio |
|
|
|
| Price: |
$0.16
| | Metrics |
| OS: |
170.4
|
M
| |
|
|
| Market cap: |
$27.3
|
M
| |
-470
|
% ROIC
|
|
Net debt:
|
$14.9
|
M
| |
|
|
|
EV:
|
$42.2
|
M
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
($8.7)
|
M
| |
|
|
|
EBIT
|
($8.8)
|
M
| |
|
|
| EPS |
($0.82)
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-15 | Dec-31-14 | Dec-31-13 | Dec-31-12 | Dec-31-11 | Dec-31-10 | Dec-31-09 | Dec-31-08 |
| Revenues | 0.0 | 0.0 | 0.0 | 0.0 | 1.2 | 0.1 | 0.7 | 0.5 |
| Revenue growth | | | | -100.0% | 1874.6% | -91.1% | 57.0% | -6.4% |
| Cost of goods sold | -11.4 | -33.6 | -27.8 | -23.4 | 1.9 | 0.4 | 2.6 | 2.1 |
| Gross profit | 11.4 | 33.6 | 27.8 | 23.4 | -0.6 | -0.3 | -1.9 | -1.7 |
| Gross margin | | | | | -49.6% | -542.9% | -268.9% | -369.2% |
| Sales and marketing | | | | | 2.6 | 1.8 | 2.6 | |
| Research and development | 2.5 | 3.6 | 2.6 | 4.3 | 3.2 | 2.8 | 1.8 | 0.3 |
| General and administrative | 8.8 | 29.0 | 23.8 | 16.9 | 29.3 | 20.6 | 15.8 | 15.4 |
| EBITA | -11.3 | -32.1 | -26.3 | -21.1 | -35.6 | -25.5 | -22.1 | -20.9 |
| EBITA margin | | | | | -2862.1% | -40436.5% | -3124.6% | -4629.5% |
| Amortization of intangibles | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | | |
| EBIT | -11.3 | -32.2 | -26.4 | -21.2 | -35.7 | -25.5 | -22.1 | -20.9 |
| EBIT margin | | | | | -2867.4% | -40538.1% | -3124.6% | -4629.5% |
| Pre-tax income | -6.8 | -33.1 | -26.7 | -14.6 | -35.9 | -25.8 | -22.8 | -20.6 |
| Income taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -2.2 |
| Tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 10.8% |
| Earnings from continuing ops | -6.8 | -33.1 | -26.7 | -14.6 | -35.9 | -25.8 | -22.8 | -18.3 |
| Earnings from discontinued ops | -0.1 | -5.4 | -6.2 | -8.2 | | | | |
| Net income | -6.8 | -38.5 | -32.8 | -22.9 | -38.0 | -28.3 | -22.8 | -18.3 |
| Net margin | | | | | -3053.7% | -44890.5% | -3220.3% | -4066.3% |
| |
| Diluted EPS | ($0.70) | ($4.49) | ($0.16) | ($0.10) | ($0.27) | ($0.22) | ($0.22) | ($0.20) |
| Shares outstanding (diluted) | 9.7 | 7.4 | 168.1 | 147.0 | 133.6 | 118.4 | 101.9 | 89.8 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|